The pathogenesis of osteoporosis

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Changes in the calciotropic hormones with age contribute significantly to the pathogenesis of osteoporosis. In both postmenopausal (Type I) and senile osteoporosis (Type II) it is common to find reduced levels of serum 1,25-dihydroxyvitamin D and malabsorption of calcium. In Type I patients a reduced level of serum parathyroid hormone causes a real decrease in serum 1,25-dihydroxyvitamin D production and malabsorption of calcium, whereas in Type II patients the decline in 1α-hydroxylase activity in the kidney causes a decline in serum 1,25-dihydroxyvitamin D which leads to malabsorption of calcium and secondary hyperparathyroidism. In the final analysis both pathways lead to bone loss. In some Type II patients there may be a decline also in the function or number of the vitamin D-binding receptors in the gut. Treatment of patients with vitamin D analogues, however, normalizes calcium absorption and improves calcium balance. The improvement in calcium balance reduces bone resorption and prevents further bone loss; in addition recent studies have shown that therapy with vitamin D analogues leads to a reduction in fracture incidence.

Original languageEnglish
Pages (from-to)215-227
Number of pages13
JournalBone and Mineral
Volume9
Issue number3
DOIs
StatePublished - 1990

Fingerprint

Osteoporosis
Calcium
Vitamin D
Bone
Serum
Bone and Bones
Fracture Fixation
Calcitriol Receptors
Secondary Hyperparathyroidism
Bone Resorption
Mixed Function Oxygenases
Parathyroid Hormone
Hormones
Kidney
Incidence
Therapeutics
1,25-dihydroxyvitamin D

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Endocrinology
  • Surgery

Cite this

The pathogenesis of osteoporosis. / Gallagher, John Christopher G.

In: Bone and Mineral, Vol. 9, No. 3, 1990, p. 215-227.

Research output: Contribution to journalArticle

@article{08c96a3b6d2746f29d41a7a05d78c6f7,
title = "The pathogenesis of osteoporosis",
abstract = "Changes in the calciotropic hormones with age contribute significantly to the pathogenesis of osteoporosis. In both postmenopausal (Type I) and senile osteoporosis (Type II) it is common to find reduced levels of serum 1,25-dihydroxyvitamin D and malabsorption of calcium. In Type I patients a reduced level of serum parathyroid hormone causes a real decrease in serum 1,25-dihydroxyvitamin D production and malabsorption of calcium, whereas in Type II patients the decline in 1α-hydroxylase activity in the kidney causes a decline in serum 1,25-dihydroxyvitamin D which leads to malabsorption of calcium and secondary hyperparathyroidism. In the final analysis both pathways lead to bone loss. In some Type II patients there may be a decline also in the function or number of the vitamin D-binding receptors in the gut. Treatment of patients with vitamin D analogues, however, normalizes calcium absorption and improves calcium balance. The improvement in calcium balance reduces bone resorption and prevents further bone loss; in addition recent studies have shown that therapy with vitamin D analogues leads to a reduction in fracture incidence.",
author = "Gallagher, {John Christopher G.}",
year = "1990",
doi = "10.1016/0169-6009(90)90039-I",
language = "English",
volume = "9",
pages = "215--227",
journal = "Bone and Mineral",
issn = "0169-6009",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - The pathogenesis of osteoporosis

AU - Gallagher, John Christopher G.

PY - 1990

Y1 - 1990

N2 - Changes in the calciotropic hormones with age contribute significantly to the pathogenesis of osteoporosis. In both postmenopausal (Type I) and senile osteoporosis (Type II) it is common to find reduced levels of serum 1,25-dihydroxyvitamin D and malabsorption of calcium. In Type I patients a reduced level of serum parathyroid hormone causes a real decrease in serum 1,25-dihydroxyvitamin D production and malabsorption of calcium, whereas in Type II patients the decline in 1α-hydroxylase activity in the kidney causes a decline in serum 1,25-dihydroxyvitamin D which leads to malabsorption of calcium and secondary hyperparathyroidism. In the final analysis both pathways lead to bone loss. In some Type II patients there may be a decline also in the function or number of the vitamin D-binding receptors in the gut. Treatment of patients with vitamin D analogues, however, normalizes calcium absorption and improves calcium balance. The improvement in calcium balance reduces bone resorption and prevents further bone loss; in addition recent studies have shown that therapy with vitamin D analogues leads to a reduction in fracture incidence.

AB - Changes in the calciotropic hormones with age contribute significantly to the pathogenesis of osteoporosis. In both postmenopausal (Type I) and senile osteoporosis (Type II) it is common to find reduced levels of serum 1,25-dihydroxyvitamin D and malabsorption of calcium. In Type I patients a reduced level of serum parathyroid hormone causes a real decrease in serum 1,25-dihydroxyvitamin D production and malabsorption of calcium, whereas in Type II patients the decline in 1α-hydroxylase activity in the kidney causes a decline in serum 1,25-dihydroxyvitamin D which leads to malabsorption of calcium and secondary hyperparathyroidism. In the final analysis both pathways lead to bone loss. In some Type II patients there may be a decline also in the function or number of the vitamin D-binding receptors in the gut. Treatment of patients with vitamin D analogues, however, normalizes calcium absorption and improves calcium balance. The improvement in calcium balance reduces bone resorption and prevents further bone loss; in addition recent studies have shown that therapy with vitamin D analogues leads to a reduction in fracture incidence.

UR - http://www.scopus.com/inward/record.url?scp=0025352580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025352580&partnerID=8YFLogxK

U2 - 10.1016/0169-6009(90)90039-I

DO - 10.1016/0169-6009(90)90039-I

M3 - Article

VL - 9

SP - 215

EP - 227

JO - Bone and Mineral

JF - Bone and Mineral

SN - 0169-6009

IS - 3

ER -